Advanced search
Publication Cover
Hematology Volume 27, 2022 - Issue 1
Submit an article Journal homepage
2,304
Views
2
CrossRef citations to date
0
Altmetric
Case Report

JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?

Francesco Tarantinia Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari “Aldo Moro”, Bari, ItalyView further author information
,
Cosimo Cumboa Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari “Aldo Moro”, Bari, ItalyView further author information
,
Antonella Zagariaa Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari “Aldo Moro”, Bari, ItalyView further author information
,
Elisa Parciantea Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari “Aldo Moro”, Bari, ItalyView further author information
,
Luisa Anellia Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari “Aldo Moro”, Bari, ItalyView further author information
,
Nicoletta Coccaroa Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari “Aldo Moro”, Bari, ItalyView further author information
,
Giuseppina Totaa Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari “Aldo Moro”, Bari, ItalyView further author information
,
Crescenzio Francesco Minervinia Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari “Aldo Moro”, Bari, ItalyView further author information
,
Immacolata Redavida Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari “Aldo Moro”, Bari, ItalyView further author information
,
Antonella Russo Rossia Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari “Aldo Moro”, Bari, ItalyView further author information
,
Maria Rosa Conservaa Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari “Aldo Moro”, Bari, ItalyView further author information
,
Giorgina Specchiab School of Medicine, University of Bari “Aldo Moro”, Bari, ItalyView further author information
,
Pellegrino Mustoa Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari “Aldo Moro”, Bari, ItalyView further author information
&
Francesco Albanoa Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari “Aldo Moro”, Bari, ItalyCorrespondence[email protected]
View further author information
 show all
Pages 842-846 | Published online: 08 Aug 2022

Figures & data

Figure 1. Different possible scenarios of BCR-ABL1 and JAK2 (V617F) co-occurrence in MPNs. (A) A CML patient can show the JAK2 mutation at diagnosis and present a ‘hybrid’ phenotype. (B) A CML patient can acquire the JAK2 mutation during follow-up, together with a phenotype change. (C) A JAK2 mutated Ph-MPN can acquire BCR-ABL1 during follow-up and change the phenotype. CML: chronic myeloid leukemia; Ph-MPN: Philadelphia-negative myeloproliferative neoplasm; PLT: platelets; HCT: hematocrit; WBC: white blood cells.

Figure 1. Different possible scenarios of BCR-ABL1 and JAK2 (V617F) co-occurrence in MPNs. (A) A CML patient can show the JAK2 mutation at diagnosis and present a ‘hybrid’ phenotype. (B) A CML patient can acquire the JAK2 mutation during follow-up, together with a phenotype change. (C) A JAK2 mutated Ph-MPN can acquire BCR-ABL1 during follow-up and change the phenotype. CML: chronic myeloid leukemia; Ph-MPN: Philadelphia-negative myeloproliferative neoplasm; PLT: platelets; HCT: hematocrit; WBC: white blood cells.

Figure 2. BCR-ABL1 and JAK2 (V617F) kinetics during the CML follow-up. JAK2 V617F remained stable with minor fluctuations independent of BCR-ABL1 kinetics. The evaluations shown refer to the 2016–2022 time range. IS: international scale; MR: molecular response; NR: non responder; VAF: variant allele frequency.

Figure 2. BCR-ABL1 and JAK2 (V617F) kinetics during the CML follow-up. JAK2 V617F remained stable with minor fluctuations independent of BCR-ABL1 kinetics. The evaluations shown refer to the 2016–2022 time range. IS: international scale; MR: molecular response; NR: non responder; VAF: variant allele frequency.
Supplemental material

Supplemental Table

Download MS Word (94.8 KB)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.